Skip to main content
OpenTrials
Completed

NCT Number: NCT02626871

Atrial Fibrillation, Stroke, and Bleeding in Patients Undergoing Aortic Biovalve Implantation

The primary purpose of the FIN-bioAVR registry is to assess the incidence of AF, strokes and major bleeding events in patients undergoing aortic valve replacement. This retrospective multicenter registry will include 850 patients with aortic valve replacement using bioprosthesis.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients undergoing aortic valve bioprosthesis implantation

Exclusion criteria

  • mechanical heart valves in any position

Treatment and study plan

Primary outcomes

  1. Stroke

    Time frame: 10 years

  2. Mortality

    Time frame: 10 years

  3. atrial fibrillation

    Time frame: 10 years

  4. major bleeding

    Time frame: 10 years

Sponsors and collaborators

Lead sponsor

University of Turku

Other

Collaborators

  • Helsinki University Central Hospital
  • Kuopio University Hospital
  • Oulu University Hospital

Registry information

Acronym: CAREAVR

Important dates

Study start
2002
Primary completion
2015
Study completion
2015
First posted
Dec 10, 2015
Registry last updated
May 4, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.